Why Is MEDPACE HLDGS INC (MEDP) Stock Up Today?

MEDP stock rose 14.71% to $605.82 on Wednesday, driven by strong Q2 2026 earnings results and an upgraded revenue outlook. The company reported 17% revenue growth, improved backlog conversion, and a constructive July environment with lower cancellations. Medpace also raised its 2026 revenue forecast to a range of $2.805B to $2.885B, signaling continued business momentum.

What Happened

Medpace delivered robust Q2 2026 results with double-digit revenue growth and improved profit margins. The company cited strong demand and record bookings as key contributors to its performance. Medpace also noted a significant backlog conversion and updated its 2026 revenue and earnings per share outlook. These developments were highlighted in a recent earnings call on July 23, 2026, where executives outlined the company’s improved operational and financial metrics. The updated guidance and performance metrics reinforced the company’s strong market position in the contract research organization (CRO) sector, contributing to the stock’s sharp rise.

What The Data Shows

The stock’s recent price trend shows a 14.2% increase over the last eight sessions, from $532.49 to $607.92. Medpace’s fundamentals reflect a market cap of $15.2B, a P/E ratio of 33.2, and trailing twelve-month revenue growth of 24.2%. The company maintains a net margin of 17.2%, indicating strong profitability. In terms of insider activity, one insider sold $7.4M in shares in the last 90 days. Congressional trades show four buys and two sells in the same period, with one individual making three purchases between February and May 2026.

What To Watch

The company’s updated 2026 guidance and strong Q2 results suggest continued momentum. Investors should monitor the company’s next earnings report and any further updates to its financial outlook.